Drug Approval | February 14, 2022
Zydus gets 180 days of shared exclusivity for Roflumilast tablets
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Key takeaways of recent quarter & conference call highlights
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
Adds five years of market exclusivity on approval
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry
Subscribe To Our Newsletter & Stay Updated
